Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCCS/EADO 2016 | The use of mouse models in melanoma with brain metastases to test new therapies

Clemens Krepler, MD of the Wistar Institute, Philadelphia, PA, provides an insight into the research on brain metastases in melanoma. Prof. Krepler believes that there is a need for biomarkers here. He states that a lot of patients do respond very well to therapy, both targeted therapy and immunotherapy, but still tend to develop brain metastases, which is fatal since the brain is very sensitive. Therefore, there is a need to find ways of preventing tumor cells from going to the brain. Using mouse model that are also used in his lab for other projects, patient tumors are taken from their brain lesions, and put into the mouse. This creates a mouse with brain metastases that novel therapies and second-line therapies can be tested on.
Recorded at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria.